Open AccessCell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Author(s) -
Liu Mei,
Li Zhiyang,
Yang Jingjing,
Jiang Yanyun,
Chen Zhongsi,
Ali Zeeshan,
He gyue,
Wang Zhifei
Publication year - 2016
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12266
Subject(s) - breast cancer , targeted therapy , subtyping , medicine , monoclonal antibody , cancer , cancer therapy , computational biology , immunology , antibody , biology , computer science , programming language
Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell‐specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell‐specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic‐targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non‐antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.